Faes Farma stock
Price history
+8.89% over the period1 year: from €4.61 (November 17, 2025) to €5.02 (November 17, 2026), +8.89%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | €5.02 |
| October 30, 2026 | €4.82 |
| September 30, 2026 | €4.66 |
| August 31, 2026 | €4.51 |
| July 31, 2026 | €4.56 |
| June 30, 2026 | €4.59 |
| May 29, 2026 | €4.66 |
| April 30, 2026 | €4.86 |
| March 31, 2026 | €4.66 |
| February 27, 2026 | €5.20 |
| January 30, 2026 | €5.23 |
| December 31, 2025 | €5.16 |
| November 28, 2025 | €4.76 |
| November 17, 2025 | €4.61 |
At a glance
The company
Researches, develops, produces and markets pharmaceutical products, healthcare specialties, animal nutrition products and pharmaceutical raw materials
Latest results
Quarter to September 30, 2026 · EPS €0.05
TickerLandia's take on Faes Farma
- Pricier than usual relative to earnings: P/E on the latest fiscal year 20 vs a median of 14 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 19 vs 19 (−1%) in a group of 10.
- Strong point: Dividend (75/100 in its group). Weak point: Profitability (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.90% from the 52-week high
Analysts · 5 analysts
Average target€5.56+11.06% vs. price
Buy 3 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Faes Farma
Compared with similar companies: high dividend, low risk, and low price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow30
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 14.6 24 EV/EBITDA 15.2 47 P/E (trailing 12 months) 18.7 27 Price/book 2.03 28 Price/sales 2.14 23 Profitabilitylow34
How much it earns on revenue and capital.
Metric Value Position in group ROE 11.2% 36 ROA 5.0% 25 Operating margin 13.0% 22 Gross margin 65.2% 51 Net margin 10.9% 36 Earnings stabilityaverage56
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.5% 49 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +10.74% 62 Revenue growth (year over year) +17.40% 64 Earnings growth (year over year) +8.87% 65 Financial strengthaverage42
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.58 29 Current ratio 2.63 67 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.70 18 Interest coverage 19.3 55 Dividendhigh75
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 27 years 80 Dividend yield 2.6% 72 Payout ratio 47.4% 72 Market momentumstrong61
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +12.15% 83 Relative strength (6 months) −3.67% 51 1-year return +8.68% 47 Distance from 200-day average +6.74% 64 Risklow28
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 19.2% 30 Volatility (60 days) 21.9% 27 Beta (1 year) 0.48 26
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Faes Farma is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Faes Farma's P/E today is 19.8, above the median of its last 10 fiscal years (14.1; between 9.78 and 22.3 from 2016 to 2025). Faes Farma's P/E (trailing 12 months): 18.7, in line with the median of a group of 10 similar companies (19.0).
Compared with 10 similar companies
| Metric | Faes Farma | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 18.7 | Middle | |
| Forward P/E | 14.6 | Middle | |
| Operating margin | 13.0% | Low | |
| ROE | 11.2% | Middle | |
| Debt/equity | 0.58 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Faes Farma. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€172.08M
Latest quarter · Q3 2026
Net income
€17.25M
Latest quarter · Q3 2026
Quarterly net margin
10.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €1.58B
- P/E
- 18.7
- EPS
- €0.27
- Volume
- 211.69K
- Daily trading
- €684.45K
- Dividend yield
- 2.55%
- Last ex-dividend on July 2, 2026
How Faes Farma is changing
All resultsRevenue grew 8.8% a year on average over the last 5 years
Operating margin fell from 22.1% to 14.2%
Less cash than profit: free cash flow equal to 53% of net income
Returns
Faes Farma returns with dividends
€1,000 invested in Faes Farma 5 years ago, on November 17, 2021, would be worth €1,888 today with dividends reinvested: +88.81% in total, +13.56% per year. On price alone it would be €1,495 (+49.54%).
| Period | Faes Farma | IBEX 35 | €1,000 becomes |
|---|---|---|---|
| 1 month | +7.26% | +3.21% | €1,073 |
| 6 months | +9.03% | +13.19% | €1,090 |
| Year to date | −2.71% | +15.25% | €973 |
| 1 year | +11.78% | +23.34% | €1,118 |
| 3 years | +84.93% | +104.34% | €1,849 |
| 5 years | +88.81% | +121.79% | €1,888 |
| 10 years | +139.08% | +128.80% | €2,391 |
Over the last 6 months it has done better than 19% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment
The chart in detail
Faes Farma: technical analysis
Faes Farma shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 72.0% below its all-time closing high (€17.86, March 29, 2007).
- Trend
- No clear trend
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +6.74%
Active signals
Golden cross: the 50-session average has crossed above the 200-session average.
since November 11, 2026
Support and resistance
Price areas where Faes Farma has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€5.42+8.18%2 touches, last on February 13, 2026
- Resistance€5.18+3.29%2 touches, last on February 27, 2026
- Last price€5.01
- Support€5.00−0.20%3 touches, last on October 15, 2026
- Support€4.79−4.32%4 touches, last on September 29, 2026
- Support€4.69−6.39%2 touches, last on July 2, 2026
Volatility and risk
Over the last year it has moved less than the IBEX 35.
- Beta (1 year) vs IBEX 35
- 0.48
- Volatility (60 sessions, annualised)
- 21.9%
- Largest fall in the last year
- −19.24%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Faes Farma: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Faes Farma has been January: +5.60% on average, positive in 18 years out of 26. The weakest has been December: −2.41% on average, positive in 9 years out of 26. November, the current month, has been positive in 16 years out of 26 (+0.78% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.60% | +5.27% | 18 of 26 |
| February | +3.00% | −0.11% | 13 of 27 |
| March | +0.02% | −0.41% | 12 of 27 |
| April | +1.69% | +4.30% | 15 of 27 |
| May | −1.95% | −2.12% | 9 of 27 |
| June | −1.63% | −0.80% | 11 of 27 |
| July | −0.67% | −0.94% | 11 of 27 |
| August | −0.23% | 0.00% | 13 of 27 |
| September | −0.17% | −0.25% | 12 of 27 |
| October | +0.89% | +2.06% | 15 of 27 |
| November | +0.78% | +2.54% | 16 of 26 |
| December | −2.41% | −2.03% | 9 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Faes Farma and its competitors
Prescription and healthcare products, along with the raw materials used to make them, form the core of Faes Farma's activity, and the company sells them internationally. Its medicines cover several therapeutic areas, while a separate line supplies nutrition and health products for animals. The group also engages in chemical products, foodstuffs, cosmetics and dietetics services. Founded in 1933, it holds patents, trademarks, registered brands and equity interests, and it invests in securities and real estate.
- Headquarters
- Leioa, Spain
- Employees
- 2,677
- Founded
- 1933
- Chief executive
- Eduardo de la Cuadra
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Faes FarmaFAE | $1.73B | 13.0% | 18.7 | +9.03% |
| FagronFAGR | $1.9B | 14.3% | 18.8 | +0.21% |
| AlmirallALM | $2.53B | 9.6% | 32.1 | −7.24% |
| PharmaNutraPHN | $875.44M | 21.7% | 35.0 | −3.45% |
| Siegfried HoldingSFZN | $3.53B | 16.7% | 17.3 | −14.20% |
| Laboratorios Farmaceuticos RoviROVI | $3.93B | 20.2% | 17.4 | +16.20% |
Same industry or related industries, similar size. Compare Faes Farma with its competitors · Full profile
